2026 GLP–1 Consumer Survey
Reported
Anticipated
2026 Healthline GLP–1 Consumer Survey – Sample size: 1,007 total = 720 currently taking a GLP–1, 203 took a GLP–1 in the past, 84 currently considering a GLP–1. 53% female and 47% male.
59%
63%
Appetite control
75%
81%
Weight loss
29%
49%
Energy
and mobility
37%
50%
Confidence
and body image
improvement
38%
44%
Better A1C or
blood sugar levels
20%
36%
Sleep quality
Expectations come from respondents considering a GLP–1; reported experiences come from people both formerly and currently taking a GLP–1.
Core benefits of GLP–1 use:
A1C and blood sugar management reported by:
43%
7 - 12 months
25%
fewer than
3 months
26%
3 - 6 months
63%
3 or more years
of treatment
55%
1 - 2 years
83%
7 - 12 months
74%
3 - 6 months
78%
3 or more years
of treatment
76%
1 - 2 years
66%
fewer than
3 months
Weight loss reported by:
Reported GLP–1 use benefits based on time
on treatment:
